Systematic Coronary Risk Evaluation 2 (SCORE2)

Use SCORE2 and SCORE2-OP to estimate 10-year fatal and non-fatal cardiovascular risk by ESC region, age, sex, smoking, blood pressure, and lipids. Primary prevention; not for type 2 diabetes.

SCORE2 / SCORE2-OP (10-year CVD risk)

European Society of Cardiology–aligned models for 10-year risk of fatal and non-fatal cardiovascular disease. Ages 40–69 use SCORE2; ages 70–89 use the older-population (SCORE2-OP) predictor. Select your country risk region. Not for people with known CVD or type 2 diabetes.

Age (years)

Sex

Risk region (ESC)

Match to ESC country grouping (e.g. charts or prevention toolbox).

Systolic BP (mmHg)

Lipid unitsmmol/Lmg/dL

Total cholesterol (mmol/L)

HDL cholesterol (mmol/L)

Current smokerType 2 diabetes mellitus

Disclaimer: Educational tool only. SCORE2 targets apparently healthy people without cardiovascular disease or diabetes; it does not replace clinician assessment or ESC national guidance.

SCORE2 / SCORE2-OP — how it works

Overview

SCORE2 estimates 10-year risk of fatal and non-fatal atherosclerotic cardiovascular disease in European populations. Models are sex-specific, adjusted for competing risks, and recalibrated to four geographical risk regions (low, moderate, high, very high CVD mortality). People aged 70–89 use the older-population extension (SCORE2-OP) with different centring and coefficients.

Primary reference: SCORE2 risk prediction algorithms (Eur Heart J 2021). Coefficients in this app match the published supplementary specification as encoded in open reference implementations (e.g. RiskScorescvd).

Predictors

Age (years)
Sex (male / female)
Smoking (current yes/no)
Systolic blood pressure (mmHg)
Total and HDL cholesterol (mmol/L in the original models; mg/dL is converted using the standard factor)
Geographical risk region (recalibration scales)

Type 2 diabetes is not part of the intended SCORE2 target population; the diabetes term in the underlying equations is fixed to zero here. Use SCORE2-Diabetes for people with diabetes.

Computation (conceptual)

Build a linear predictor from age, smoking, SBP, total cholesterol, and HDL (with age interaction terms), using sex-specific coefficients and centring (different for ages under 70 vs 70+).
Transform to a baseline cumulative incidence using sex-specific survival-type constants.
Apply region-specific calibration: 1 − exp(−exp(scale₁ + scale₂ × ln(−ln(1 − raw)))), where raw is the intermediate risk and scales depend on region, sex, and whether SCORE2 or SCORE2-OP applies.
Express as a percentage (rounded to one decimal) and assign ESC low / moderate / high bands by age.

ESC risk categories (by age)

Age	Low	Moderate	High
< 50 years	< 2.5%	2.5% to < 7.5%	≥ 7.5%
50–69 years	< 5%	5% to < 10%	≥ 10%
≥ 70 years	< 7.5%	7.5% to < 15%	≥ 15%

What is SCORE2?

Systematic Coronary Risk Evaluation 2 (SCORE2) is a set of cardiovascular risk models developed for use in European clinical practice. It estimates the 10-year probability of fatal and non-fatal atherosclerotic cardiovascular disease (CVD) in people without established cardiovascular disease who are candidates for primary prevention discussions. The models are sex-specific and were derived with methods that account for competing risks (other causes of death), which matters when communicating long-term event probabilities in general populations.

SCORE2 replaced the earlier SCORE system for many European settings because it incorporates non-fatal events (not only fatal CVD), aligns with contemporary epidemiology, and supports region-specific recalibration so that predicted risks better reflect differences in baseline CVD rates across Europe.

From SCORE to SCORE2

The original SCORE charts were widely used to visualize risk based on a small set of conventional risk factors. SCORE2 updates that approach for modern prevention guidelines: it targets a broader CVD endpoint relevant to preventive treatment decisions, uses updated statistical modelling, and explicitly provides four risk regions (low, moderate, high, and very high cardiovascular mortality) so that the same risk factor profile can map to different absolute risks depending on regional background rates.

For adults in the older age range, guideline-consistent tools often use SCORE2-OP (“older persons”), which applies a separate predictor structure and recentring appropriate to ages from roughly 70 years upward, while preserving the same overall framework of risk communication and regional calibration.

Who the tool is intended for

SCORE2 is designed for apparently healthy individuals in primary prevention, typically without known atherosclerotic CVD, and—critically—not for people with type 2 diabetes mellitus in the way SCORE2 is usually applied in guidelines. Diabetes changes baseline risk and treatment pathways; dedicated models such as SCORE2-Diabetes are intended for that population. Likewise, individuals with prior myocardial infarction, stroke, peripheral arterial disease, or other established CVD are generally managed as secondary prevention, where absolute risk scores aimed at primary prevention are not the right framing.

Age boundaries matter: SCORE2’s core presentation is centered on midlife and younger older adults (commonly discussed around ages 40–69 years in guideline materials), while SCORE2-OP extends estimation into older ages where calibration and risk communication require different handling.

Risk factors used in the model

SCORE2 uses a compact, clinically feasible set of variables:

Age, entered in whole years, because CVD risk rises steeply with ageing even when other factors are stable.
Sex, because event rates and risk factor effects differ between males and females at the population level.
Smoking status, typically as current smoker versus not, reflecting one of the most modifiable large-magnitude exposures.
Systolic blood pressure (mmHg), a central driver of stroke and coronary risk.
Total cholesterol and HDL cholesterol, usually expressed in mmol/L in European materials; mg/dL values can be converted for calculation.

These inputs are combined in a linear predictor that includes interaction terms with age, reflecting that the incremental hazard associated with blood pressure or lipids is not constant across the lifespan. After forming the core risk signal, SCORE2 applies a calibration step that depends on the selected geographical risk region and on whether the SCORE2 or SCORE2-OP parameterization applies.

Geographical risk regions

European countries differ in baseline cardiovascular mortality and incidence. SCORE2 therefore does not assume a single “European average.” Instead, users select among ESC-aligned low, moderate, high, and very high risk regions. The same individual profile can produce a lower estimated 10-year risk in a low-risk region and a higher estimated risk in a very high-risk region, which mirrors how absolute risk depends on the population context.

Choosing the correct region is not a biochemical measurement problem; it is an epidemiological assignment tied to national or regional groupings published with ESC prevention materials. Using the wrong region can materially shift perceived risk and downstream decisions, so the region should match the patient’s guideline context.

How risk categories are interpreted

Guideline-linked communication often pairs the numeric 10-year risk estimate with qualitative bands that depend on age. In common ESC-aligned presentations, thresholds differ for younger adults, adults aged roughly 50–69 years, and adults aged about 70 years and older. For example, younger adults may use lower percentage cutoffs for “moderate” and “high” concern than midlife adults, reflecting different implications of the same absolute risk at different ages.

These categories are aids to conversation; they do not replace clinician judgment, patient preferences, cost and access considerations, or additional risk modifiers (such as chronic kidney disease, familial hypercholesterolemia, inflammatory disease, or very high single-factor elevations) that guidelines may treat as special cases.

Using SCORE2 responsibly in practice

SCORE2 is best understood as a structured starting point for shared decision-making about lifestyle and preventive pharmacotherapy in primary prevention. It should be interpreted alongside blood pressure measurement quality, lipid panel timing, smoking status verification, and whether the patient truly belongs to the intended population (no established CVD; diabetes handled with the appropriate tool).

Limitations are inherent to all population models: they reflect average effects in cohorts used for development and calibration, may perform differently in ethnic minority groups or migrants if baseline risk differs from the calibration source, and cannot capture every determinant of atherosclerosis (family history intensity, lipoprotein(a), detailed metabolic phenotype, social determinants, etc.). Clinicians often combine scores with qualitative risk modifiers recommended by contemporary prevention guidelines.

How this calculator implements SCORE2

This calculator applies the published SCORE2 and SCORE2-OP predictor forms and the region-specific calibration constants used in ESC-aligned reference implementations. It outputs a 10-year fatal and non-fatal CVD risk percentage (rounded to one decimal place), indicates whether the SCORE2 or SCORE2-OP pathway was used based on age, and maps the result to ESC-style low, moderate, and high categories for the patient’s age band. Lipids may be entered in mmol/L or converted from mg/dL using a standard cholesterol conversion factor.

If type 2 diabetes is indicated, SCORE2 is not the appropriate primary tool; users should seek diabetes-specific risk estimation consistent with current ESC guidance rather than treating SCORE2 outputs as valid in that setting.